Secondary Offering of 3.1M Shares Priced at $3.25 Each by Selling Stockholder
SBC Medical Group Holdings Incorporated has announced the pricing of an underwritten secondary public offering involving 3.1 million shares of its common stock. The transaction, disclosed in an official statement released from Irvine, California, represents a significant shareholder-led sale rather than a capital-raising initiative by the company itself. The shares are being offered by Dr. Yoshiyuki Aikawa, identified as the selling stockholder, at a public offering price of $3.25 per share.
This secondary offering is structured in a way that distinguishes it from primary offerings typically undertaken by companies seeking to raise new capital. In this case, SBC Medical is not issuing new shares nor receiving any proceeds from the sale. Instead, all proceeds from the transaction will go directly to Dr. Aikawa. As a result, the offering primarily serves as a liquidity event for the selling stockholder, allowing for the monetization of a portion of his holdings in the company.
The offering includes an additional component designed to provide flexibility to the underwriters. Specifically, Dr. Aikawa has granted the underwriting team a 45-day option to purchase up to an additional 465,000 shares of common stock. This option, often referred to as an over-allotment or “greenshoe” option, is a standard feature in many public offerings. It enables underwriters to stabilize the market price of the stock following the offering and to meet excess demand if investor interest proves strong.
The transaction is expected to close on or about April 21, 2026, subject to customary closing conditions. These conditions generally include regulatory approvals, the absence of material adverse changes, and the fulfillment of contractual obligations by all parties involved. While such conditions are routine, they are an essential part of ensuring that the offering proceeds smoothly and in compliance with applicable securities laws.
From a strategic standpoint, the company emphasized that it is not participating as a seller in the offering. This distinction is important for investors evaluating the implications of the transaction. Since SBC Medical is not issuing new shares, the offering does not dilute existing shareholders’ equity in the same way a primary offering would. However, the increase in publicly available shares could still have an impact on the stock’s trading dynamics, including liquidity and price volatility.
The underwriting syndicate for the offering is led by Maxim Group LLC, which is acting as the sole book-running manager. Roth Capital Partners is participating as a co-manager. The role of the book-running manager is central to the execution of the offering, as it is responsible for coordinating the sale, determining pricing in consultation with the selling stockholder, and managing investor demand. The co-manager supports these efforts, helping to broaden distribution and facilitate the offering process.
The offering is being conducted under an effective shelf registration statement on Form S-3 that SBC Medical previously filed with the U.S. Securities and Exchange Commission (SEC). A shelf registration allows a company or selling shareholders to register securities in advance and offer them to the public at a later date without requiring a new registration process for each transaction. This mechanism provides flexibility and efficiency, enabling quicker access to capital markets when conditions are favorable.
As part of the regulatory process, the offering will be made through a prospectus supplement and an accompanying base prospectus. These documents provide detailed information about the company, the securities being offered, and the terms of the transaction. A preliminary prospectus supplement has already been filed with the SEC, and a final version will be made available once the offering is completed.
Investors are strongly encouraged to review these documents carefully before making any investment decisions. The prospectus materials include comprehensive disclosures about the company’s business operations, financial condition, risk factors, and other relevant considerations. Access to these documents is available free of charge through the SEC’s website, ensuring transparency and accessibility for all potential investors.
In addition to the SEC’s online repository, copies of the preliminary and final prospectus supplements can be obtained directly from the underwriting firms. Maxim Group LLC has provided contact details for its syndicate department, including a physical address in New York, a telephone number, and an email contact. These channels allow interested parties to request copies of the offering materials and obtain further information about the transaction.
It is important to note that this announcement does not constitute an offer to sell or a solicitation of an offer to buy securities in any jurisdiction where such actions would be unlawful. This standard disclaimer underscores the importance of compliance with securities regulations, which vary by state and country. Any sale of securities must be conducted in accordance with applicable laws, including proper registration or qualification where required.
The broader context of this offering reflects ongoing activity in the healthcare services and management sector, where companies like SBC Medical operate across multiple medical specialties through franchise and management service organization models. Such business structures enable the company to provide administrative, operational, and strategic support to a network of medical practices, enhancing efficiency and scalability.
While the offering itself does not directly impact the company’s balance sheet, it may influence market perception and investor sentiment. Secondary offerings by major shareholders can sometimes be interpreted in different ways, depending on the circumstances. In some cases, they are seen as routine portfolio management decisions, while in others they may raise questions about the selling shareholder’s outlook. However, without additional context, such interpretations remain speculative.
Ultimately, the successful completion of the offering will depend on market conditions and investor demand. Pricing at $3.25 per share reflects a balance between attracting investor interest and achieving the selling stockholder’s objectives. The inclusion of the over-allotment option further enhances the flexibility of the transaction, allowing underwriters to respond to market dynamics in real time.
As the closing date approaches, market participants will be watching closely to assess the impact of the offering on SBC Medical’s stock performance and trading activity. Increased liquidity resulting from the additional shares in circulation could benefit investors by facilitating easier buying and selling. At the same time, short-term price fluctuations are not uncommon following such transactions.
In summary, SBC Medical’s announcement outlines a well-structured secondary public offering led by a key shareholder, with established financial institutions managing the process. While the company itself is not raising capital, the transaction represents an important development in its market activity and shareholder landscape. Investors considering participation are advised to review all संबंधित filings and disclosures to make informed decisions based on a comprehensive understanding of the offering and the company’s overall position.
About SBC Medical
SBC Medical Group Holdings Incorporated is a Management Services Organization operating a wide range of franchise businesses across diverse medical fields, including advanced aesthetic healthcare, dermatology, orthopedics, fertility treatment, gynecology, dentistry, alopecia treatment (AGA), and ophthalmology. The Company manages a diverse portfolio of clinic brands and is actively expanding its global presence, particularly in the United States and Asia, through both direct operations and medical tourism initiatives. In September 2024, the Company was listed on Nasdaq, and in June 2025, it was selected for inclusion in the Russell 3000® Index, a broad benchmark of the U.S. equity market. Guided by its Group Purpose “Contributing to the well-being of people around the world through medical innovation,” SBC Medical Group Holdings Incorporated continues to provide safe, trusted, and high-quality medical services while further strengthening its international reputation for quality and trust in medical care.
